Quick Answer
RetinalGenix Technologies Inc. reported Research And Development Expense of $373.3 thousand for the year ending 2024.
- RetinalGenix Technologies Inc. showed a decrease of -28.8% in Research And Development Expense from 2023 to 2024.
- This data is from RetinalGenix Technologies Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2020 to 2024 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $98.9 thousand | Q2 2021: $159.9 thousand | Q3 2021: $200.9 thousand | Q2 2022: $135.4 thousand | Q2 2023: $152.6 thousand | Q1 2024: $83.1 thousand | Q2 2024: $82.9 thousand | Q3 2024: $103.0 thousand | Q1 2025: $13.2 thousand | Q2 2025: $14.4 thousand | Q3 2025: $20.5 thousand.
- Over the full 4 years of available data (2020 to 2024), RetinalGenix Technologies Inc.'s Research And Development Expense has declined by 13.5%.
- Historical annual values: Fiscal year 2024: $373.3 thousand | Fiscal year 2023: $524.2 thousand | Fiscal year 2021: $680.3 thousand | Fiscal year 2020: $431.6 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: